Article
Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis
Registro en:
FRANCESCONI, Glaucia et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia, v. 171, p. 349-354, 2011.
0301-486X
10.1007/s11046-010-9380-8
1573-0832
Autor
Francesconi, Glaucia
Valle, Antonio Carlos Francesconi do
Passos, Sonia Lambert
Barros, Mônica Bastos de Lima
Paes, Rodrigo de Almeida
Curi, André Luiz Land
Liporage, José
Porto, Cássio Ferreira
Gutierrez-Galhardo, Maria Clara
Resumen
Itraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis. Objective: To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Materials and methods: A bidirectional cohort study was conducted on 55 patients receiving 250 mg/day terbinafine and 249 patients receiving 100 mg/day itraconazole. The latter patients were matched for age and clinical form to the terbinafine group at a ratio of 5:1. Sporothrix schenckii was isolated by culture
from all patients (age range: 18–70 years), who were submitted to the standard care protocol consisting of
clinical and laboratory evaluation and periodic visits. Results: Cure was observed in 51 (92.7%) patients of the terbinafine group and 229 (92%) of the itraconazole group within a similar mean period of time (11.5 and 11.8 weeks, respectively). An increase in the terbinafine dose to 500 mg was necessary in two patients due to the lack of a response, and one patient presented recurrence. In the itraconazole group, two patients required a dose increase and three presented recurrence. Adverse events were equally frequent among patients receiving terbinafine (n = 4, 7.3%) and itraconazole (n = 19, 7.6%) and were generally mild without the need for drug discontinuation, except for two patients of the itraconazole group. Conclusion: Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis. 2020-05-30